A Phase 2/3 interventional study of Oncoxin and Suranix in Quality of Life, sponsored by Clinical Research Organization, Dhaka, Bangladesh. Status unknown at 1 site in Bangladesh. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-12-12.
Sponsored by Clinical Research Organization, Dhaka, Bangladesh · Phase 2/3, Interventional, and Treatment
Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma
To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib
6,745 studies on the registry are indexed under Carcinoma; 1,163 are open to participants now.
This study's planned enrollment of 60 is above the median of 45 across 5,174 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →Clinical Research Organization, Dhaka, Bangladesh is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
Dietary Supplement: Oncoxin
Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
Dietary Supplement: Oncoxin · Drug: Suranix
Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Also known as: Nexavar, Suranib
Number of patients who have prolonged survival
To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks
Time frame: 24 weeks
Reduction in serum alpha-fetoprotein level and decrease in tumor size
To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks.
Time frame: 24 weeks
This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinical Research Organization, Dhaka, Bangladesh